NewsRoom Articles - Page 2 of 247

FridayAug 14, 2026 10:00 am

Little-Known Immune Cells Bolster Anticancer Fight, Study Finds

Researchers from the University of Manchester in the UK have found that a small group of immune cells that aren’t given much attention by scientists is actually crucial in mobilizing the immune system to attack and sustain its fight against cancer. The study, whose findings appeared in the journal Immunity, explored what impact the activation or deactivation of these particular immune cells would have on the body’s response to cancer. For their study, the team designed mouse models in which it was possible to label or actually remove activated dendritic cells. Until this particular study was undertaken, it was hard for the research community to study the role of these cells during the…

FridayAug 14, 2026 9:45 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks

Regentis has passed 50% enrollment in the pivotal Phase III SAGE study of GelrinC, with recruitment completion targeted for the third quarter of 2026 and a PMA process expected to begin by the end of 2027. FDA approved a single-arm protocol using a historical microfracture control data package the company owns, and Regentis reports that the first 40 patients closely match that control group. In Europe, where GelrinC already holds CE Mark approval, surgeon training began in the third quarter of 2026 at Humanitas Research Hospital in Milan, supported by an expanded clinical site network and a newly approved manufacturing…

ThursdayAug 13, 2026 10:00 am

Global Drugmakers Earmark Billions to Ramp Up Their US Footprint

Dozens of global drugmakers are ramping up their investments in the United States in a bid to sidestep the planned tariffs on drug imports. In total, ongoing investments and planned expansions amount to approximately $500 billion. These planned investments are intended to not only reassure investors but also mitigate risks linked to global supply chains, such as the evolving tariff environment. Last September, Pfizer engaged in discussions with Trump, and the drugmaker undertook to invest about $70 billion in domestic R&D as well as manufacturing. In exchange, Trump granted the company an exemption of three years from any tariffs that are imposed on drug imports into…

ThursdayAug 13, 2026 9:00 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market

A new Japanese patent allowance follows a recent such US patent grant, strengthens protection around the organic solvent-free manufacturing process and ready-to-use liquid formulation behind GelrinC, extending the company’s intellectual property footprint into one of the world’s largest cartilage-repair markets. The process delivers a 5-fold increase in yield along with simplified production and commercial scalability, the manufacturing economics needed to make an off-the-shelf cartilage product commercially viable at scale. The milestone lands as Regentis advances European commercialization and passes the halfway mark in enrollment for its pivotal U.S. trial. Aging populations are pushing joint disease higher on the orthopedic agenda,…

WednesdayAug 12, 2026 9:00 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Researchers recognize that a large share of long-term disability accumulates independent of relapses altogether, a phenomenon researchers call progression independent of relapse activity. That shift has forced researchers to look at what is actually driving PIRA. A major suspect is chronic active lesions, sometimes called smoldering or mixed active-inactive lesions. Rather than broadly suppressing the immune system, Quantum BioPharma’s Lucid-MS is designed to inhibit myelin degradation, preserve myelin and support functional recovery. Multiple sclerosis is quietly shifting how drugmakers define success. Instead of judging a therapy mainly by…

TuesdayAug 11, 2026 10:00 am

Deadly Infection Surges, Prompts Health Officials to Caution Beachgoers

Beachgoers on the Gulf Coast in the U.S. have been urged to exercise caution in order to limit the risk of contracting a bacterial infection that has surged around the region. The flesh-eating bacteria become especially prevalent during summer in coastal water. In a press release, health authorities in Louisiana revealed that so far, nine cases of the infection have been confirmed and five of the affected people have lost their lives. The state added that over the past 10 years, about seven cases of Vibrio vulnificus infections were confirmed annually. Given that the summer is still on, confirmed infections could rise even further since the tally so far has exceeded that…

TuesdayAug 11, 2026 9:00 am

Earth Science Tech Inc. (ETST) Q1 2027 Financial and Operational Results Reflect Compounding Progress of Expansion Strategy

Earth Science Tech, a growing healthcare holding company, recently reported its Q1 2027 financial results, with key highlights including $9.0 million in revenue, $6.3 million in gross profit, $715,697 in net income, $707,131 in net cash, and $10.4 million in total assets. According to the CEO, the Q1 2027 figures reflect steady, compounding progress and are the result of a foundation built in the 2026 financial year. The company’s strategy of carefully acquiring and scaling cash-flowing assets across healthcare, pharmaceutical, and telemedicine sectors, is driving growth to support uplisting and attract institutional capital. Earth Science Tech (OTC: ETST), a diversified…

FridayAug 07, 2026 10:00 am

Spanish Patient Highlights Risks of Poorly Cooked Pork

Doctors in Spain recently handled a fascinating yet terrifying case of a patient that developed brain cancer-like symptoms and was treated as such, but additional tests brought to light a scarier cause of his illness: cysts resulting from a pork tapeworm infection. This case highlights the dangers of exposure to these worms, or eating pork that hasn’t been cooked fully. The patient’s medical mystery started with worsening headaches that lasted more than two weeks. His behavior also started changing in subtle ways, and these symptoms prompted him to visit his doctor. A CT scan conducted on his brain showed he had lesions, and the doctor feared that he had cancer that…

ThursdayAug 06, 2026 10:00 am

Liquid Biopsy Forecasts Response to Immunotherapy in Lung Cancer Patients

While immunotherapy is revolutionizing cancer therapy, response rates to these novel treatments are low and some patients that initially respond well end up becoming unresponsive. Scientists have been working to develop tools that can help in predicting which patients are likely to benefit from immunotherapy, and a new liquid biopsy has provided a simpler way to do just that for patients with advanced lung cancer. According to a study that was published in the journal Clinical Cancer Research, a team at the Kimmel Cancer Research Center at Johns Hopkins together with their collaborators was able to develop a liquid biopsy that can accurately predict which patients will benefit from immunotherapy against…

WednesdayAug 05, 2026 2:40 pm

Surgeon, Payer, Patient Win: The Economic and Workflow Advantages Positioning GelrinC as a New Standard of Care for Knee Cartilage Repair

Regentis recently received European regulatory approval for a next-generation GelrinC manufacturing process that increases production yield by 400%. The company is advancing commercialization through scalable manufacturing, surgeon training programs, and continued U.S. Phase III clinical progress. These developments reinforce Regentis' strategy of bringing innovative cartilage repair technology from clinical validation to commercial scale, with unit economics that improve as production volumes build. Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC, its innovative cell-free hydrogel implant for focal knee cartilage repair, with a value proposition that extends across the entire healthcare ecosystem. Designed to simplify treatment while improving clinical outcomes,…